Subscribe To
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Why shares of genelux corporation jumped this week
Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ...
June 1, 2023, 5:19 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...
May 25, 2023, 9:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...
May 25, 2023, 9:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Immunogen (imgn) stock surges 230% in a month: here's why
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ...
May 12, 2023, 1:42 pm
Context therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024
Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's c...
May 11, 2023, 10:08 am
Immunogen nearly triples on ovarian cancer drug phase 3 results
Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ...
May 8, 2023, 8:31 am
Immunogen stock price doubles after ovarian cancer candidate elahere aces phase 3 study
ImmunoGen Inc stock more than doubled after the company shared positive topline data from the Phase 3 confirmatory MIRASOL trial evaluating the safety...
May 3, 2023, 12:36 pm
Why immunogen stock is soaring wednesday
The company said it anticipates asking for full approval of Elahere from the FDA. The drug was granted accelerated approval in November to treat advan...
May 3, 2023, 11:53 am
Why is immunogen (imgn) stock up 125% today?
ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a Phase 3 trial for treating ...
May 3, 2023, 10:04 am
Immunogen stock more than doubles on heavy volume after positive trial data ovarian cancer treatment
Shares of Immunogen Inc. IMGN blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutica...
May 3, 2023, 9:08 am
In8bio announces new preclinical data in ovarian cancer to be presented at asgct 26th annual meeting
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as o...
May 2, 2023, 9:08 pm
Immunogen shares pop on 1q sales of ovarian cancer drug
ImmunoGen Inc shares rocketed higher Friday after the company's first quarter sales impressed investors. The Massachusetts-based company posted reve...
April 28, 2023, 1:57 pm
Why shares of immunogen jumped friday
ImmunoGen's ovarian cancer therapy, Elahere, has had a strong launch. The company increased its revenue...
April 28, 2023, 12:03 pm
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for cyclin e1 expression as predictive marker for clinical benefit from
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for ...
April 26, 2023, 10:00 am
Panavance therapeutics announces positive preclinical data demonstrating gp-2250 single-agent and combination activity for the treatment of ovarian cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ...
April 17, 2023, 12:05 pm
ovarian cancer drugs market size to grow by us$ 9,857 mn by 2032, driven by innovation and portfolio extension – market.us
The ovarian cancer market is poised for growth during the forecast period, driven by the increasing bur...
April 13, 2023, 8:51 pm